|
Dean J.
Kereiakes, MD Elliott M.
Antman, MD Michael
Argenziano, MD Alain Cribier,
MD Martin B. Leon,
MD Gilles
Montalescot, MD, PhD
Bios Dr. Kereiakes is medical director at the Carl and Edyth Lindner Center for Research and Education in Cincinnati, Ohio, chief executive officer and director of research at The Ohio Heart Health Center in Cincinnati, and professor of clinical medicine at Ohio State University in Columbus. He received his MD from the University of Cincinnati. His postgraduate training included an internship and residency at the University of California, San Francisco, a senior residency at Massachusetts General Hospital in Boston, and a chief residency at the University of California, San Francisco. He was a fellow in adult cardiology at the University of California, San Francisco, and in coronary angioplasty at the San Francisco Heart Institute and Sequoia Hospital. Dr. Kereiakes has been an investigator for most of the interventional technologies introduced in the last decade and has performed more than 20,000 catheterization laboratory procedures. Dr. Kereiakes is a fellow of the American College of Cardiology (ACC) and a member of the American Heart Association (AHA) Committee on Cardiac Catheterization and Intervention. He was a member of the Joint ACC/AHA Task Force Committees that wrote guidelines for both coronary angioplasty and unstable angina. Dr. Kereiakes was selected as an outstanding alumnus of the University of Cincinnati School of Medicine. He was also named in Who’s Who in America, Who’s Who in Medicine and Healthcare, and Best Doctors in America, and received the Cincinnati Business Courier Health Care Hero-Innovator award and the Ohio Valley AHA’s Kaplan Visionary Award for cardiovascular research. In addition to lecturing nationally and internationally, Dr. Kereiakes is active as a clinical and scientific investigator and has participated in more than 500 clinical research protocols. He has published more than 400 journal articles, abstracts, and book chapters. He serves on the editorial boards of the American Heart Journal, The Journal of Invasive Cardiology, the American Journal of Cardiology, and Circulation, and is a section editor for both Circulation (Expert Opinions) and MedReviews (New Drugs and Devices). Disclosure Presentation will not include discussion of off-label/unapproved
uses of drugs or devices.
Dr. Antman is director of the Samuel A. Levine Cardiac Unit in the Cardiovascular Division of the Brigham and Women’s Hospital in Boston, Massachusetts. He received his MD from the Columbia University College of Physicians and Surgeons and served as resident in internal medicine at Columbia Presbyterian Medical Center. After completing his cardiology fellowship at the Peter Bent Brigham Hospital, he joined the faculty of Harvard Medical School where he is now a professor of medicine. Dr. Antman has published widely on cardiovascular pharmacology and electrophysiology. He is a senior investigator in the TIMI research program and was the principal investigator for the TIMI 9, TIMI 11, TIMI 14, and ENTIRE-TIMI 23 trials dealing with new treatments for acute coronary syndromes. He is now the principal investigator for ExTRACT-TIMI 25, comparing enoxaparin with unfractionated heparin for ST-elevation myocardial infarction patients receiving fibrinolysis. In addition, Dr. Antman has published on the use of serum cardiac markers for diagnosis and prognosis of patients with unstable angina and acute myocardial infarction. As an outgrowth of a major interest in meta-analysis of randomized trials of cardiovascular therapies, he was the chair of the steering committee for the Magnesium in Coronaries (MAGIC) study, sponsored by the National Heart, Lung, and Blood Institute of the National Institutes of Health. Dr. Antman has been an active member of several American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines Committees, and is the chairman of the ACC/AHA Committee to Revise the Guideline for Management of ST-elevation Myocardial Infarction. In 2001, he was named the vice chairman of the overall ACC/AHA Task Force on Practice Guidelines and became its chairman in 2003. He is also a member of the AHA Clinical Cardiology Program Committee, of the AHA Science Advisory and Coordinating Committee, and of the ACC Quality Strategic Oversight Committee. He is the recipient of the Gifted Teacher Award of the ACC (2003). Disclosure Presentation will include discussion of off-label/unapproved
uses of drugs or devices.
Dr. Argenziano is the director of the Surgical Arrhythmia
Program and Robotic Cardiac Surgery at Columbia University Medical
Center in New York, and is an attending surgeon in the division
of cardiothoracic surgery. He is also an assistant professor of
surgery at Columbia University College of Physicians and Surgeons.
He received his MD from Columbia University College of Physicians
and Surgeons and completed his internship and residency in general
surgery at Columbia University Medical Center. He is a diplomate
of the American Board of Thoracic Surgery, American Board of Surgery,
and the National Board of Medical Examiners. Disclosure Presentation will not include discussion of off-label/unapproved
uses of drugs or devices.
Dr. Cribier is a professor of medicine and head of
the Department of Cardiology at University Hopital Charles Nicolle,
Rouen, France. He received his medical training at the University
of Paris, France, and at Cedars-Sinai Medical Center, Los Angeles,
California. He is the former president of the French Society of
Interventional Cardiology and a cofounder of the Indo-French Foundation
for Interventional Cardiology. Disclosure Presentation will include discussion of off-label/unapproved
uses of drugs or devices.
Dr. Leon is a clinical professor of medicine at Georgetown
University Medical Center, Washington, DC, and the director and
CEO of the Cardiovascular Research Foundation at Lenox Hill Hospital,
New York. He graduated from the Yale University School of Medicine
in New Haven, Connecticut, where he also completed formal training
in internal medicine and cardiology. Dr. Leon was a clinical associate,
senior investigator, and, later (1985), director of the Catheterization
Laboratories in the Cardiology Branch of the National Heart, Lung,
and Blood Institute at the National Institutes of Health. In 1990,
he joined a prestigious group of interventional cardiologists to
form the Washington Cardiology Center and the Cardiovascular Research
Foundation. Disclosure Presentation will not include discussion of off-label/unapproved
uses of drugs or devices.
Professor Montalescot is professor of cardiology and head of the Intensive Cardiology Care Unit at Hôpital la Pitié-Salpétrière in Paris, France. He earned his MD at Université Paris XII in 1987 and was a fellow at Massachusetts General Hospital in Boston from 1987 – 1988. He has extensive experience in basic and clinical research and is a regular adviser for research committees including the French Ministry of Research and Education. He has served on several task forces on antithrombotic drugs and acute coronary syndromes. His main expertise is in the field of coronary thrombosis, ranging from pathogenesis to therapeutics. Professor Montalescot has been an investigator for many antithrombotic drugs developed in the past 10 years, as well as for many new interventional technologies. He has been the principal investigator of several randomized trials including ADMIRAL and ARMADA. Professor Montalescot is an active member of a number of organizations with a major interest in education and research in thromboembolic diseases. He was chairman of the Working Group on Thrombosis of the French Society of Cardiology and is a member of the nucleus of the Working Group on Thrombosis and Platelets of the European Society of Cardiology. Professor Montalescot is the recipient of several awards in France including the J. Valade Prize from the Fondation de France and the J. Escalle Award from the National Academy of Medicine. He has published many peer-reviewed articles in such journals as The New England Journal of Medicine and Circulation, and has delivered many invited international lectures. Disclosure Presentation will not include discussion of off-label/unapproved
uses of drugs or devices.
For technical support, call 1-877-893-6808, or send an email to support@vioworks.com |
